TCR2 Therapeutics | 15-12G: Notice of termination of registration of a class of securities under Section 12(g) (and amendment thereto)
Jun 12, 2023 19:00
TCR2 Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
Jun 2, 2023 04:45
TCR2 Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
Jun 2, 2023 04:44
TCR2 Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
Jun 2, 2023 04:43
TCR2 Therapeutics | S-8 POS: S-8 POS
Jun 2, 2023 04:41
TCR2 Therapeutics | S-8 POS: S-8 POS
Jun 2, 2023 04:41
TCR2 Therapeutics | S-8 POS: S-8 POS
Jun 2, 2023 04:40
TCR2 Therapeutics | S-8 POS: S-8 POS
Jun 2, 2023 04:39
TCR2 Therapeutics | S-8 POS: S-8 POS
Jun 2, 2023 04:38
TCR2 Therapeutics | 8-K: Current report
Jun 2, 2023 04:10
TCR2 Therapeutics | 8-K: Current report
May 31, 2023 04:17
TCR2 Therapeutics | DEFA14A: Others
May 25, 2023 04:53
TCR2 Therapeutics | 8-K: Current report
May 25, 2023 04:47
TCR2 Therapeutics | DEFA14A: Others
May 22, 2023 19:33
TCR2 Therapeutics | 8-K: Current report
May 22, 2023 19:31
TCR2 Therapeutics | 8-K: TCR 2 Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 11, 2023 19:00
TCR2 Therapeutics | DEFM14A: Definitive proxy statement relating to merger or acquisition
Apr 21, 2023 04:50
TCR2 Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Mar 23, 2023 19:51
TCR2 Therapeutics | 8-K: TCR 2 Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
Mar 23, 2023 19:00
TCR2 Therapeutics | 8-K: Current report
Mar 11, 2023 05:50
No Data
No Data